Gilead Sciences, Inc. (GILD)
| Market Cap | 132.62B |
| Revenue (ttm) | 28.75B |
| Net Income (ttm) | 480.00M |
| Shares Out | 1.25B |
| EPS (ttm) | 0.38 |
| PE Ratio | 279.95 |
| Forward PE | 13.37 |
| Dividend | $3.16 (2.97%) |
| Ex-Dividend Date | Mar 14, 2025 |
| Volume | 8,177,340 |
| Open | 106.06 |
| Previous Close | 105.51 |
| Day's Range | 105.11 - 106.56 |
| 52-Week Range | 62.07 - 119.96 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 106.52 (+0.13%) |
| Earnings Date | Apr 24, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $106.52, which is an increase of 0.13% from the latest price.
News
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an agg...
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzu...
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Top 3 Nasdaq 100 stocks rising as it moves into a correction
The Nasdaq 100 Index has slumped into a technical correction this year, falling by over 16% from its highest level in January. It has crashed to a low of $18,520, its lowest level since August 9 of la...
Final Trades: Gilead Sciences, Amazon, Alphabet and KLA Corp.
The Investment Committee give you their top stocks to watch for the second half.
Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)
We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable income strategy for Opti...
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences shows strong growth in its HIV and oncology franchises, with BIKTARVY and TRODELVY driving significant revenue increases in 2024. LIVDELZI's conditional approvals in the U.S. and Europ...
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding
Gilead Sciences is the maker of Biktarvy and Descovy, two drugs used to treat the virus.
Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly
The Investment Committee debate the latest Calls of the Day.
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment port...
Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) Leerink Partners Global Healthcare Conference Call March 11, 2025 10:40 AM ET Company Participants Cindy Perettie - Executive Vice President and Global Head, Kite ...
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavi...
5 Big Biopharmaceutical Stocks That Are Finding Favor
AbbVie, Gilead Sciences, Amgen, and Johnson & Johnson have held steady amid a fluctuating market.
Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants T...
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.
Why Gilead Sciences Remains A Buy After A 40% Rally
Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by...
MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy® in Advanced Breast Cancer
LAUSANNE, Switzerland & BARCELONA, Spain--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to...
European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company's Marketin...
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the trea...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Ca...